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Strengths and limitations of this study
 ► Multiple data types and sources are integrated 
to characterise multidisciplinary care in different 
settings.
 ► A two-stage research design facilitates better tar-
geting of observations and interviews in the second 
stage.
 ► A strategy of intensive data collection using multiple 
methods is used to ensure that site-specific data is 
interpreted within its local context.
 ► Findings will be based on a rigorous and extensive 
observational characterisation of Australian oncolo-
gy outpatient services.
AbStrACt
Introduction An understanding of the real-world provision 
of oncology outpatient services can help maintain service 
quality in the face of escalating demand and tight budgets, 
by informing the design of interventions that improve the 
effectiveness or efficiency of provision. The aims of this 
study are threefold. First, to develop an understanding of 
cancer services in outpatient clinics by characterising the 
organisation and practice of multidisciplinary care (MDC). 
Second, to explore the key areas of: (a) clinical decision-
making and (b) engagement with patients’ supportive 
needs. Third, to identify barriers to, and facilitators of, the 
delivery of quality care in these settings.
Methods and analysis A suite of mixed-methods studies 
will be implemented at six hospitals providing cancer 
outpatient clinics, with a staged roll-out. In Stage One, 
we will examine policies, use unstructured observations 
and undertake interviews with key health professionals 
to characterise the organisation and delivery of MDC. 
In Stage Two, observations of practice will continue, to 
deepen our understanding, and to inform two focused 
studies. The first will explore decision-making practices 
and the second will examine how staff engage with 
patients’ needs; both studies involve interviews, to 
complement observation. As part of the study of supportive 
care, we will examine the implications of an introduction 
of patient-reported measures (PRMs) into care, adding 
surveys to interviews before and after PRMs roll-out. Data 
analysis will account for site-specific and cross-site issues 
using an adapted Qualitative Rapid Appraisal, Rigorous 
Analysis approach. Quantitative data from clinician surveys 
will be statistically analysed and triangulated with the 
related qualitative study findings.
Ethics and dissemination Ethical approval was 
granted by South Eastern Sydney Local Health District 
Human Research Ethics Committee (no. 18/207). 
Findings will be shared with participating hospitals 
and widely disseminated through publications and 
presentations.
IntroduCtIon
In the developed world, invasive cancer is the 
leading cause of death.1 Globally, the inci-
dence of cancer is increasing2; in Australia, 
cancer incidence is projected to reach 150 000 
new cases per year by 2020.3 Survival rates 
are improving, with over 400 000 Australians 
living 5 years post cancer diagnosis.3 Cancer is 
understood as a condition requiring medical 
and supportive care services from diagnosis 
through long-term survivorship.4 5 Multidis-
ciplinary care (MDC) is accepted as a best 
practice model of care provision for oncology 
services in Australia, and in advanced health 
systems globally.6–9 MDC seeks to promote 
equitable, evidence-based care by a team 
that combines relevant expertise and enables 
patients to be involved in decision-making 
concerning their care.5 10
Work has been undertaken to translate 
MDC principles into practice; but significant 
challenges remain.10–12 In this regard, substan-
tial evidence points to gaps between optimal 
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Figure 1 Key elements of MDC. Source: Authors’ 
conceptualisation of MDC. MDC, multidisciplinary care.
evidence-based care and current care.13–17 A review of 
research literature, national health sector reports and 
local cancer plans identified three key interconnected 
elements of MDC: diverse professional expertise, clinical 
decision-making and addressing patients’ supportive care 
needs. In figure 1 the coordination of care is positioned 
to reflect the way in which it binds and encompasses these 
elements.
Patient needs
In addition to medical anti-cancer treatment with cura-
tive intent, people with cancer also need medical (eg, 
pain relief) and non-medical supportive care (eg, infor-
mation needs). The challenges of addressing supportive 
needs are an ongoing concern in oncology.18–21 Meeting 
these needs requires identification, prioritisation, timely 
access to relevant professional expertise and treatment 
planning (eg, in consultation with a psychologist).18–21 In 
general, identification of support needs in cancer care has 
not been systematic. Rather, routine care has relied on 
the clinical acumen of individual clinicians who identify 
needs during consultations and make appropriate refer-
rals. Language spoken and level of health literacy also 
remain challenges in order to ‘pitch’ information at the 
level most suitable for each patient. Routinely collecting 
information from patients, through patient reported 
measures (PRMs), has been promoted as a mechanism 
to identify unmet supportive needs.22–24 The Edmonton 
Symptom Assessment Scale,25 Distress Thermometer26 are 
PRMs which some of the outpatient clinics (OPCs) will be 
introducing into routine cancer care during the period 
of study, and are expected to change the management of 
patients’ supportive needs.27–29 This study focuses on the 
provider perspective; the patient’s support networks are 
also important for addressing supportive needs, but these 
are beyond the study’s scope.
Diverse professional expertise
MDC is overseen by a core team which, while varying by 
cancer type, usually consists of pathologists, radiologists, 
medical oncologists, radiation oncologists, surgeons, 
nurses and allied health professionals.5 10 30 Other 
specialist expertise can also be part of the core team, or 
can be added as required. This may include expertise 
such as in palliative care or pre-rehabilitation and post-re-
habilitation over the course of the patient’s journey.5 This 
approach is intended to use cross-disciplinary expertise 
to the fullest benefit of the patient and offer shared deci-
sion-making mechanisms for clinicians.10 31 To develop 
an understanding of MDC we therefore need to harness 
the views of a diverse range of professionals and observe 
interprofessional collaboration in practice.
Decision-making
Multidisciplinary team meetings (MDTMs) are a fulcrum 
for the clinical coordination of MDC.11 12 Research 
suggests that MDTM discussions influence diagnosis, 
staging and treatment planning.32–34 It is important to 
understand the organisation of MDTMs and the resources 
required to support them. Studies reveal variability in 
the organisation of MDTMs, who is discussed and when, 
and the ways that clinicians engage to support clinical 
decision-making.9 While MDTMs play a central role, 
clinicians make decisions outside MDTMs, without any 
consultation during routine care provision, or in consul-
tation with other clinicians who may or may not be part 
of the team. In addition, decisions can be made at the 
meetings but evidence suggests that the recommenda-
tions are not always followed and in many meetings there 
can be disagreements in opinion.35 How these issues are 
managed with the patient are likely to be highly individu-
alised. We also seek to understand this behaviour.
Coordinated care
Among the top priorities for coordination are: (1) 
ongoing screening of patients’ supportive needs and 
appropriate care in response and (2) the timely and 
appropriate delivery of care across the patient’s journey.36 
Public hospital OPCs are tasked with providing care for 
diverse types of cancer across the patient journey, from 
diagnosis, through treatment and into survivorship. The 
models of coordination employed may be non-uniform; 
hybrid approaches may be used within a setting (eg, simul-
taneously offering tumour stream-specialised care coor-
dination, with generalised care coordinators covering 
all others).37 38 Sub-optimal coordination can lead to 
fragmented care, conflicting information provided to 
patients, impaired access to appropriate services and inef-
ficient use of the time and energy of health professionals 
and patients.21 39 40
Research framework
The investigation described in this paper is the first major 
phase of field research undertaken by the newly estab-
lished National Health and Medical Research Council 
Centre for Research Excellence in Implementation 
Science in Oncology (CRE-ISO), administered by the 
Australian Institute for Health Innovation at Macquarie 
University. In healthcare, implementation science focuses 
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on understanding processes and methods for supporting 
the uptake and integration of effective interventions 
to improve healthcare practices and outcomes.41 The 
research described here will characterise MDC provi-
sion in two Sydney metropolitan Local Health Districts 
(LHDs), government agencies responsible for managing 
and providing public health services within a specified 
geography, usually of approximately one million resi-
dents in order to provide a foundational understanding 
of the realities of oncology service provision. This under-
standing will inform subsequent phases of research 
undertaken by the Centre and will guide the selection of 
implementation approaches, some of which will focus on 
developing and testing tailored interventions to address 
identified evidence-practice gaps.
Critical to this study is engagement with the context of 
service provision and its complexity; of the ‘interacting 
and interdependent’ components of a health service that 
comprise MDC provision in hospitals.42 Multiple sources 
of data will be harvested and integrated, exploring the 
formalised processes and local practices undertaken 
within the interconnected networks of semi-autono-
mous professionals that together shape care provision.43 
Systems of care provision in these settings are rarely static, 
and opportunities will be taken to examine the uptake of 
new practices, such as the introduction of PRMs, to learn 
about the processes that inhibit or promote effective 
adoption. This research will also seek to identify generic 
barriers and facilitators that impede or promote best 
practice, as background information to assist with the 
design of future interventions.
Research aims (RA)
The study aims to:
RA1. Develop understanding of cancer services in OPCs 
by characterising the organisation and practice of MDC;
RA2. Explore, in-depth, selected key elements of MDC:
i. Clinical decision-making in MDC and how doctors 
engage with decision-making support mechanisms in 
practice; and
ii. How health professionals engage with patients’ sup-
portive needs before and immediately after the intro-
duction of PRMs.
RA3. Identify general barriers to, and facilitators of, the 
provision of MDC.
A mixed-methods research design will be adopted: 
largely comprised of a variety of qualitative methods, 
complemented by a single quantitative survey. Methods 
adapted from ethnography will be harnessed, to facilitate 
intensive and efficient data collection; rapid ethnography 
will be used to reduce the burden of research on organisa-
tions and participants while maintaining rigour and rich-
ness.44 45 Careful thought has been given to the demands 
of multisite research and we adopt recommended strat-
egies used to enhance validity and maintain capacity to 
adequately engage with the complexities of the settings.46
The methodological principles embedded in the design 
are: exploring everyday practices and the organisational 
relations that shape them, by observing participants at 
work in OPC settings; harnessing a plurality of partici-
pant perspectives, by interviewing professionals about 
their work and generating rich descriptive accounts of 
MDC contexts by using analytical and interpretative 
approaches formulated for multisite data.47 A critical 
realist philosophical position is taken, which is comprised 
of a realist ontological assumption and a critical episte-
mology.48 49 From this position it is assumed that a given 
account may not perfectly reflect reality; rather, accounts 
may be contextually and structurally mediated, offering 
partial insight into complex phenomena.50 51
Design
A staged design will be used. Prior to study commence-
ment, profiles and structural descriptions of each hospital 
setting were developed, using publicly-available informa-
tion. In Stage One, an overview of the organisation of prac-
tice and models of care will be derived through interviews 
with ‘Navigators’ (eg, OPC staff with an overview of care 
pathways such as nurse unit managers or care coordi-
nators), review of unpublished policies and procedures 
and unstructured observations of care provision. In Stage 
Two, we enrich the accounts of these settings through 
additional observation in OPCs. Together, these methods 
address the first research aim (RA1) and provide a foun-
dation for the second (RA2) and third (RA3).
Stage Two also includes focused studies, undertaken in 
parallel. In Study 2.1, interviews with doctors and observa-
tions of cancer MDTMs provide insight into clinical deci-
sion-making practices in MDC and how doctors engage 
with decision-making support mechanisms (RA2.i). 
Engagement with patients’ supportive needs will be 
explored in Study 2.2 ( RA2. ii), using a two part, mixed-
method design consisting of interviews with health profes-
sionals, observation of cancer MDTMs and a ‘clinician 
readiness’ survey; all research elements will be performed 
before introduction of new PRMs, and repeated after they 
have been introduced.
Barriers and facilitators to the provision of MDC (RA3) 
will be elicited as part of the interviews in each study and 
enhanced by our observational studies in Stages One and 
Two. The study design is informed by the Consolidated 
Criteria for Reporting Qualitative Research.52 The study 
will run from the 28th of February, 2019, up to the 31st of 
December, 2020.
Selection of sites and participants
The investigation will be undertaken within two metro-
politan LHDs, each containing three participating public 
hospitals with OPCs. Collectively, the OPCs offer an 
extensive range of consultation, coordination, wellness 
and outpatient treatment services. Each LHD contains 
two large hospitals which provide an extensive range of 
services and a smaller hospital offering a more limited 
range of services, closely linked with larger centres (eg, 
including the provision of teleconferencing for meetings).
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Table 1 Study design features







Review of policies and 
procedures relevant to 
interview discussion
Navigator (n=8-16) Decision-making 
(n=3-8) Supportive needs (n=4-10)
n/a Cancer MDTMs 
(n=3–8)
Initial:





Review of policies and 
procedures relevant to 
interview discussion
Decision-making (n=15–30) n/a Cancer MDTMs 
(n=3–8)
Ongoing:
OPCs (n=15) Individual 
(n=7)Study 2.2. 








Estimated totals n/a 60–124 30–50 9–24
OPCs (n=30-40) Individual 
(n=10)
Table key
Undertaken at all sites
Predominantly undertaken in LHD 1
Predominantly undertaken in LHD 2
*1 observation session= half day or 3 to 4 hrs.
LHD, Local Health District; MDTM, multidisciplinary team meeting; OPCs, outpatient clinics.
Sites and meetings: In Stage One all sites will be studied, 
to understand each hospital setting. In Stage Two, 
maximum variation sampling53 will be used to allocate 
the ‘continuing observation’ sessions to participating 
sites. As there are differences in the services between sites 
(eg, some hospitals offer a smaller range), observation 
sessions will be allocated to best capture the diverse range 
of practices and processes useful in the characterisation 
of MDC within and across sites. Purposive sampling will 
be used to select the MDTMs approached to participate. 
We will generate a sample comprising a range of tumour 
streams including common and rarer cancers. Study 2.1 
will largely be conducted in one LHD, with study 2.2 in 
the other.
Participants: The participant inclusion criteria for inter-
views, surveys and health professional observations is 
generally broad: core medical staff (eg, medical oncolo-
gists, surgeons, radiation oncologists), nursing staff (eg, 
clinical nurse consultants, cancer care coordinators) 
and allied health staff (eg, social workers, psychologists). 
However, participation in Stage One ‘Navigator interviews’ 
will be restricted to staff with an overview of care path-
ways (eg, cancer care coordinators, nurse unit managers, 
managers of clinical streams). Similarly, in Study 2.2 the 
‘clinician decision-making’ interviews will be undertaken 
with specialist doctors (eg, medical oncologists, surgeons, 
radiation oncologists) working in cancer services.
Recruitment: Information about the research including 
its aims, an introduction to the researchers undertaking 
data collection, contact details and participant informa-
tion sheets will be disseminated through email, flyers 
and posters, and through information sessions for target 
professional groups at each site. Snowball sampling will 
also be used; participants will be encouraged to discuss 
the project with colleagues. Letters will be sent to the 
Chairpersons of cancer MDTMs and to the authorities 
responsible for the OPCs, to provide information about 
the research and request permission for the observations. 
These letters will include ‘Health Professional Informa-
tion Sheets’ which recipients will be encouraged to share 
with relevant colleagues as a component of pre-approval 
consultation.
Sample size ranges: The Study design features, presented 
in table 1, summarise the stages of the research, the data 
collected in each stage and the target number of observa-
tions, interviews and surveys. The sample sizes designated 
for the interview components are guided by princi-
ples identified in reported research literature, as well 
as Malterud, Siersma and Guassora’s (2016) model for 
generating ‘information power’ in qualitative studies. The 
model accounts for the following factors when estimating 
a sample range: the study aim, specificity of the sample, 
the envisioned quality of the interview interaction, anal-
ysis strategy and established theory.54 The number of 
proposed interviews in Study 2.2. is also guided by the 
sample size needed for the clinician readiness survey that 
is undertaken as part of the interview. The sample size 
allocated for the individual health professional obser-
vations reflects the narrow and specific focus of gaining 
a deep understanding of the roles these professionals 
play in MDC. The number of sessions proposed for the 
observations of the OPCs and MDTMs are comparable 
with similar qualitative studies55 and are appropriate for 
multisite ethnographic studies.56
Research Team: The investigation will be overseen by a 
team with extensive experience in health services and 
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quality improvement research, including leaders in 
implementation science and oncology. Fieldwork will 
be guided by principal investigators with direct clinical 
and research experience in oncology service provision, in 
leadership roles in the LHDs. Data will be collected by GA 
(Senior Research Fellow, PhD, male), BNGE (Research 
Fellow, PhD, female) and TW (Research Associate, 
Masters, female) who are trained in qualitative, quanti-
tative and mixed-methods investigation. Each of these 
researchers has fieldwork experience across a range of 
health services. Qualitative analysis will be conducted by 
BNGE and TW, while YT (Research Fellow, PhD, female) 
will analyse quantitative data. Appropriately qualified 
health professionals who join the research team for Stage 
Two will be trained and supervised.
data collection
As part of protocol development, reviews of the literature 
were conducted to conceptualise and identify key issues 
in MDC provision and to scope the methodological schol-
arship relevant to the design. Publicly-available annual 
reports and cancer plans from each health district were 
analysed to generate a description of cancer services at 
each hospital. These profiles were used to map key areas 
for data collection. Implementation science approaches 
emphasise the importance of the local context of adop-
tion and engagement with its stakeholders.41–43 During 
this stage, input was sought from oncology management 
to ensure the local relevance of the research and the feasi-
bility of the proposed methods.
Stage one - multisite characterisation study
Interviews: Semi-structured ‘Navigator’ interviews will be 
undertaken with professionals who have overview roles 
(eg, cancer care coordinator), oriented by care pathway 
maps, to establish the models of care and processes 
involved in the patient journey (n=8 to 16).57 58 The 
care pathway maps were derived from the stages of MDC 
depicted by Fennell, Das, Clauser, Petrelli and Salner,59 
focused on the diagnosis and OPC treatment stages 
(figure 2). Through the interviews, maps will be reworked 
to reflect the Australian services context, and the differing 
trajectories followed by different: (a) tumour streams 
(accounting for tumour-specific services) and (b) risk 
categories and complexity. Where interviewees refer to 
specific policies and procedures, documentation will be 
formally requested to help situate the discussion within its 
policy context. Interviews are expected to take approxi-
mately 40 min and will be audio-recorded and transcribed.
Observations: Three types of observations will be made 
in the research:
 ► Unstructured observations of OPCs will provide an 
understanding of the real-world, routine organisa-
tion and actual delivery of MDC in these settings 
(eg, we will observe ad hoc and planned collabora-
tion between professionals from differing disciplines 
during the care delivery process; n=15 to 25).
 ► Observations of individual health professionals will 
capture the key activities undertaken, to understand 
how their work contributes to the provision of MDC 
(n=3 to 6 individual health professionals observed for 
half or all of their day).
 ► Observations of MDTMs will be conducted using 
a semi-structured template (figure 3) informed by 
previous MDTM observational research to guide what 
we observe and record, and systematise our descrip-
tion of meetings (n=3 to 8 meetings).11 60 Field notes 
will record observations of: professional groups in 
attendance, specific roles, support provided to admin-
ister the meeting (ie, technology), organisation of 
cases, clinical decision-making, patient-centred care 
and organisation of follow-up.
All observations will be recorded in handwritten field 
notes which will be used to generate rich accounts of care.
Transition to Stage Two: During Stage One, we will pilot 
elements of the clinician interviews about decision-making 
(n=3 to 8) and patients’ supportive needs (n=4 to 10) to 
be undertaken in Stage Two, and interview prompts will 
be refined. Where eligible health professionals indicate 
interest in joining the research team for Stage Two field-
work, they will be briefed and provided with necessary 
training and support.
Stage two - MdC studies
This stage will enrich accounts of MDC provision via 
‘ongoing characterisation’ (ie, n=3 to 6 further observa-
tions of individual health and n=15 unstructured obser-
vations of OPCs), at the same time contextualising the 
focused studies detailed below.
Study 2.1 - clinical decision-making
Interviews: Doctors will participate in semi-structured inter-
views that explore their decision-making practices and 
their engagement with support mechanisms (n=15 to 30). 
Topics will include their perceptions of decision-making 
mechanisms, the decision-making support available to 
them, their own decision-making practices and their use 
of MDTMs at key points in the patient journey. A concep-
tual map of the patient journey (figure 4) will be used 
to orient the interview, with questions tailored to each 
stage. Barriers to and drivers of efficient clinical deci-
sion-making will be explored. Interviews are expected to 
take approximately 40 min and will be audio-recorded 
and transcribed.
Observation of MDTMs: Meetings will be observed using 
a semi-structured template (figure 3), focussing on the 
‘clinical decision-making’ component (n=3–8). Obser-
vational data will capture information about this deci-
sion-making mechanism and contextualise interviews.
Study 2.2 Patients’ supportive needs
Interviews: Prior to the introduction of PRMs, semi-struc-
tured interviews will be conducted with health profes-
sionals about how they engage with patients’ supportive 
needs in their current practice (n=15 to 30). Topics will 
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Figure 2 MDC interventions at transitions in cancer care. Source: Fennell et al59 (adapted from Zapka et al).65 MDC, 
multidisciplinary care.
include: models of care, their individual role, identifica-
tion and screening, management and any barriers and 
facilitators experienced in identifying and responding to 
supportive needs. The interviews will also explore prepa-
rations for and expectations of PRMs.
Following the adoption of PRMs, health professionals 
will again participate in semi-structured interviews (n=15 
to 30). These will focus on the adoption and implications 
of PRMs in relation to the topics addressed in pre-introduc-
tion interviews. Pre-introduction and post-introduction 
interviews are expected to take approximately 40 min and 
will be audio-recorded and transcribed.
Surveys: An eight-item Clinician Readiness Survey61 will 
be completed by health professionals before and after the 
adoption of PRMs (n=30 to 50 in each phase). The survey 
will assess the current level of preparedness, and changes 
over time. This survey will take approximately 5 min to 
complete and will be performed as part of the interviews 
and will also be distributed more widely to achieve the 
desired sample size.
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Figure 3 MDTM data collection template. Source: 
Developed by authors based on Harris et al60 and Rankin et 
al.11 MDC, multidisciplinary care; MDTM, multidisciplinary 
team meetings.
Figure 4 Mapping of points of diagnosis and treatment decision-making in MDC. Source: Authors’ adaption of Fennell et al.59 
GP, general practitioner; MDC, multidisciplinary care; MDTM, multidisciplinary team meetings.
Observation of MDTMs: Meetings will be observed using 
a semi-structured template (figure 3), focussing on the 
‘patient-centred care and supportive care needs’ compo-
nent (n=3 to 8). Data will capture information about 
engagement with supportive needs in MDTMs and 
contextualise the interviews.
data analysis
Interview data: Basic descriptive data collected during 
interviews (eg, listing of team members involved in 
different points of the patient journey) will be collated 
across interviews then categorised and organised within 
a matrix. The discursive data will be coded by two 
researchers and thematically analysed, oriented by an 
inductive approach.62 Where process maps are used (eg, 
navigator and decision-making interviews), these will 
frame the analysis. Constant comparative analysis will be 
applied to interpret data gathered before and after the 
introduction of PRMs. This strategy accounts for the cross-
site, multiple-source nature of the data. Our approach for 
making sense of cross-site data is informed by the ‘Qual-
itative Rapid Appraisal, Rigorous Analysis’ methodology 
developed by Phillips et al.45 First, all ‘like’ data (eg, all 
interview data) is analysed at a site, followed by intrasite 
analysis of all data from one OPC. Intersite analysis is 
then employed to consider the data across the sites.45
Observational data: Field notes will be indexed to iden-
tify the specific setting/MDTM meeting, key processes 
and events and study focus. The notes will be integrated 
within hospital cancer service profiles to elaborate descrip-
tions of OPC settings (ie, the organisational features of 
care). Field notes from MDTM and OPC observations will 
then be developed into accounts that contextualise data 
collected in the focused studies. Data collected from indi-
vidual health professional observations will be developed 
into an account of the role.
Clinician readiness survey data: Analysis will include a 
repeated-measures analysis of variance to test for differ-
ences in clinician attitudes before and after PRMs roll-out. 
If possible, subgroup analyses will test for differences in 
attitudes between different demographic and clinical 
subgroups. The quantitative data will be used to comple-
ment the interview data on this topic. Based on known 
effect sizes from results of the Willis et al61 paper using the 
Outcome Measurement Questionnaire to assess change 
in response to training, using a power of 0.8 and alpha 
of 0.05, the minimum sample size was estimated as n=32 
participants (ie, to detect a change in mean scale score 
from 4.09 pre-introduction to 4.49 post-introduction, 
with a SD of 0.57).
Measurement of outcomes
The main outcomes of the investigation are aligned with 
the aims. Through this investigation we will generate a 
rich and comprehensive description of the organisation 
and practice of MDC. We will document practices of clin-
ical decision-making including the role of the MDT in 
such practice. We will produce an account of how patient 
supportive needs are engaged with and the implications 
that the introduction of PRMs has for this engagement. 
The factors which impede or promote practice will be 
identified and used to inform subsequent CRE-ISO 
activity.
For the qualitatively-driven research, assessment of 
the outcomes involves judgement of the adequacy with 
which the research aims were addressed. This is largely 
reliant on the quality of the data collected and the rigour 
of its analysis. Sufficiently detailed data are needed from 
a range of sources to produce rich descriptions of MDC 
practice, including its diversity. Fieldwork and analytical 
strategies should allow findings to be situated within OPC 
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contexts as well as revealing points of connection and 
contradiction between sites. Characterisation of MDC 
provision will be achieved through credible, adequately 
complex and well-grounded accounts. Multi-method data 
collection (including a quantitative component) allows 
for consideration of various sources of input, and trian-
gulation; a team-based approach to analysis will facilitate 
ongoing reflection and monitoring.
EthICS And dISSEMInAtIon
Informed written consent will be obtained from inter-
viewees and from health professionals who are individ-
ually observed. Interview and observation arrangements 
will be made with health professionals at least 1 week 
in advance to ensure they have time to prepare. Partic-
ipants may withdraw, without justification, up to 1 week 
post interview/observation or whenever the data is 
de-identified.
Posters will be displayed, and information sheets will 
be available during observational sessions so that those 
present can raise concerns or decline participation. This 
can be done at any time up until the observational data is 
collected. The research team will not collect any informa-
tion about patients and, guided by health professionals, 
will minimise exposure to direct patient interactions. 
Researchers will answer questions posed about their pres-
ence and provide information sheets that contain ethics 
committee details. In the event of participants experi-
encing discomfort or distress arising from the research, 
researchers will facilitate access to appropriate support 
services.
Data storage and protection: Data will be stored on a pass-
word-protected computer and on a secure university 
server, accessible only to the research team. Data will be 
de-identified and separated from participant identifiers. 
Research records will be retained for at least 5 years post-
study completion or last publication, in accordance with 
Section 2.1.1 of the Australian Code for the Conduct of 
Responsible Research (2007)63 before secure destruction.
Dissemination: Findings will be disseminated to 
academics, professionals and the public through publica-
tions and presentations. Tailored reports will be provided 
to participating hospitals and presentations given to 
participating professional groups.
Patient and public involvement statement
The coordinating research institution routinely consults 
with patients, their representatives and the general 
public, to ensure that adequate input is secured for 
research programme; a key partner is the Consumers 
Health Forum of Australia. This specific project was 
developed without detailed patient involvement; patients 
were not invited to comment on the study design or to 
the writing or editing of this protocol. This project will 
help us to describe service structure and organisation, 
and to learn from the perspectives of MDC providers. 
The experiences of patients are vital to understanding 
these services, including their views on the barriers and 
facilitators to high-quality care. Patient experiences will 
be engaged with dedicated, patient-centred studies within 
the CRE-ISO programme of research. For example, in 
preparation, we have already looked at data from UK 
Patient Experience Surveys,64 and are in the process of 
accessing Australian data from a similar source.64
Impact & Significance
The research seeks to capture a diverse range of practices 
and processes useful in the characterisation of MDC, with 
attention to site-specific nuances that may be relevant to 
future improvement efforts. The accumulative character-
isation will be combined with focused, in-depth studies 
of clinical decision-making and processes for meeting 
patients’ supportive care needs. The research involves 
rigorous and extensive observations of Australian public 
oncology OPCs and MDTMs; it offers a substantial oppor-
tunity for the generation of new and critical insights. 
The findings will serve as a foundation for the design of 
studies to address identified evidence-practice gaps in 
cancer care.
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